NCT06770764View on ClinicalTrials.gov

Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Advanced Solid TumorsMetastatic Solid Tumors
Interventions
DRUG

ODC-IL2

ODC-IL2 as a single agent infused IV over 60 minutes on Days 1 and 15 of a 28 day cycle.

Trial Locations (1)

85258

RECRUITING

HonorHealth, Scottsdale

All Listed Sponsors
lead

Trutino Biosciences Inc.

INDUSTRY